18-160
Showing 1 - 25 of >10,000
Primary Sjögren's Syndrome Trial in Yantai (Placebo, RC18 240 mg, RC18 160 mg)
Completed
- Primary Sjögren's Syndrome
- Placebo
- +2 more
-
Yantai, Shandong, ChinaRemegen,Ltd.
Jan 7, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Guangzhou (RC18 160mg, RC18 240mg)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- RC18 160mg
- RC18 240mg
-
Guangzhou, Guangdong, Chinathe Third Affiliated Hospital,Sun Yat-Sen University
Jan 7, 2022
Neuromyelitis Optica Spectrum Disorders Trial in Beijing (Placebo, RC18 160 mg)
Recruiting
- Neuromyelitis Optica Spectrum Disorders
- Placebo
- RC18 160 mg
-
Beijing, Beijing, ChinaBeijing Hospital
Jan 9, 2022
Herpes Simplex Trial in Tokyo (HSVTI Formulation 1, HSVTI Formulation 2, Placebo)
Not yet recruiting
- Herpes Simplex
- HSVTI Formulation 1
- +2 more
-
Tokyo, JapanGSK Investigational Site
Aug 4, 2023
Systemic Myasthenia Gravis Trial in Beijing (RC18 160mg, RC18 240 mg)
Active, not recruiting
- Systemic Myasthenia Gravis
- RC18 160mg
- RC18 240 mg
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital,Capital Medical University
Jan 9, 2022
Systemic Lupus Erythematosus Trial in Yantai (Placebo plus standard therapy, RC18 160 mg plus standard therapy)
Active, not recruiting
- Systemic Lupus Erythematosus
- Placebo plus standard therapy
- RC18 160 mg plus standard therapy
-
Yantai, Shandong, ChinaRemegen，ltd.
Jan 7, 2022
Moderate and Severe RheumatoId Arthritis Trial in Beijing (Placebo plus MTX, RC18 160 mg plus MTX)
Active, not recruiting
- Moderate and Severe RheumatoId Arthritis
- Placebo plus MTX
- RC18 160 mg plus MTX
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jan 9, 2022
IgA Nephropathy Trial in Beijing (RC18 160mg, RC18 240mg, )
Completed
- IgA Nephropathy
- RC18 160mg
- +2 more
-
Beijing, Beijing, ChinaPeking University people's hospital
Jul 16, 2021
CZ Using the Detection of HPV DNA and CINtec Plus
Completed
- Algorithm for Cervix Carcinoma Screening
- HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)
- +2 more
-
Praha, Czech Republic, CzechiaAeskulab Patologie, ks
Oct 11, 2022
Lupus Nephritis Trial in China (Telitacicept 240 mg, Telitacicept 160 mg, Placebo)
Not yet recruiting
- Lupus Nephritis
- Telitacicept 240 mg
- +2 more
-
Hefei, Anhui, China
- +44 more
Jan 11, 2023
Hypertension, Pulmonary Trial in Worldwide (Riociguat (Adempas, BAY63-2521))
Active, not recruiting
- Hypertension, Pulmonary
- Riociguat (Adempas, BAY63-2521)
-
Cali, Valle Del Cauca, Colombia
- +15 more
Jan 18, 2023
IgA Nephropathy Trial in United States (Telitacicept 160mg, Telitacicept 240mg, Placebo)
Recruiting
- IgA Nephropathy
- Telitacicept 160mg
- +2 more
-
Los Angeles, California
- +15 more
Feb 7, 2022
Primary Sjogren's Syndrome Trial in China (Telitacicept 80 mg, Telitacicept 160 mg, Placebo)
Not yet recruiting
- Primary Sjogren's Syndrome
- Telitacicept 80 mg
- +2 more
-
Bengbu, Anhui, China
- +67 more
Jan 5, 2023
Systemic Lupus Erythematosus Trial in Beijing (Placebo plus standard therapy, RC18 80 mg plus standard therapy, RC18 160 mg plus
Completed
- Systemic Lupus Erythematosus
- Placebo plus standard therapy
- +3 more
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Mar 2, 2020
Healthy Trial in Yantai (Tai Ai(RC18) 80mg, Tai Ai(RC18) 160mg, RC18 240mg)
Completed
- Healthy
- Tai Ai(RC18) 80mg
- +2 more
-
Yantai, Shandong, ChinaRemegen，ltd.
Jan 16, 2020
160 Participants Aged 18-35 Years and Obese (BMI =30) Open to Men and Women of All Ethnicity Trial in Los Angeles (Glycemic
Completed
- 160 Participants Aged 18-35 Years and Obese (BMI ≥30) Open to Men and Women of All Ethnicity
- Glycemic Load
- Resistance Training
-
Los Angeles, CaliforniaUniversity of California, Los Angeles
Nov 12, 2020
COPD Trial (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid, Tiotropium 18 mcg capsule inhaled once daily +
Completed
- COPD
- Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid
- +2 more
- (no location specified)
Aug 18, 2020
Meningococcal B Disease Trial in Worldwide (rLP2086 vaccine, Pediatric HAV vaccine)
Completed
- Meningococcal B Disease
- rLP2086 vaccine
- Pediatric HAV vaccine
-
Canberra, Garran, Australian Capital Territory, Australia
- +24 more
Aug 30, 2021
Generalized Myasthenia Gravis Trial in Worldwide (ARGX-113)
Completed
- Generalized Myasthenia Gravis
- ARGX-113
-
Carlsbad, California
- +51 more
Jul 8, 2022
Generalized Myasthenia Gravis Trial in Worldwide (efgartigimod PH20 SC)
Active, not recruiting
- Generalized Myasthenia Gravis
- efgartigimod PH20 SC
-
Carlsbad, California
- +46 more
Jul 5, 2022
Migraine Trial in Worldwide (Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3)
Recruiting
- Migraine
- Erenumab Dose 1
- +3 more
-
Aurora, Colorado
- +88 more
Feb 1, 2023
Migraine Trial in Worldwide (Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3)
Recruiting
- Migraine
- Erenumab Dose 1
- +3 more
-
Aurora, Colorado
- +82 more
Dec 6, 2022
Clinical Criteria in for Treatment of Maternal Hypertension
Not yet recruiting
- Maternal Hypertension
- Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension
- Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension
- (no location specified)
Jun 5, 2023
Acute Gastroenteritis Trial in Liuzhou (Low-dose vaccine, High-dose vaccine, Placebo (containing aluminum))
Recruiting
- Acute Gastroenteritis
- Low-dose vaccine
- +3 more
-
Liuzhou, Guangxi, ChinaLiuzhou Center for Disease Control and Prevention
Sep 2, 2022